Initiation of CD8 T cell-mediated BBB disruption and neuronal involvement in experimental cerebral malaria
实验性脑型疟疾中 CD8 T 细胞介导的 BBB 破坏和神经元受累的启动
基本信息
- 批准号:10219208
- 负责人:
- 金额:$ 4.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAmericanAnatomyAnimalsAntigen-Presenting CellsAreaBiological MarkersBlood - brain barrier anatomyBrainC57BL/6 MouseCD8-Positive T-LymphocytesCellsCerebral MalariaCessation of lifeClinicalCognitive deficitsComplicationDataDendritic CellsDevelopmentDiagnosisDiseaseDisease ProgressionDrug resistanceEdemaEtiologyEventFeedbackFutureGenetic TranscriptionHumanImmuneImmune systemImmunologistImmunotherapyIn Situ HybridizationInfectionKnock-outKnockout MiceKnowledgeLeadLeftLeukocytesMagnetic Resonance ImagingMajor Histocompatibility ComplexMalariaMediatingMethodsModelingMusNeurologicNeuronsOutcomeParasite resistanceParasitesPathogenesisPathogenicityPathologicPathologyPatient-Focused OutcomesPermeabilityPlasmodium bergheiPlasmodium falciparumProteinsRNAResearchRoleSeveritiesSeverity of illnessSurvivorsT cell responseTestingTherapeuticTherapeutic InterventionTight JunctionsTimeTissuesTransgenic MiceTumor-infiltrating immune cellsUp-RegulationVaccinesVascular Endothelial Growth FactorsVascular PermeabilitiesWorkWorld Health Organizationblood-brain barrier disruptionblood-brain barrier permeabilizationcell typeconditional knockoutcytotoxiccytotoxic CD8 T cellsdefined contributionfield studyimprovedin vivoinnovationinsightknockout animalmalaria infectionmortalitymouse modelnervous system disordernovelnovel imaging techniquenovel therapeuticstargeted treatmenttherapeutic targettranscription factorvaccine development
项目摘要
Project Summary/Abstract:
Plasmodium falciparum, deemed “deadliest parasite in humans” by World Health Organization is the causative
agent of the disease known as malaria. Malaria infections result in approximately half a million deaths per year.
Cerebral malaria (CM) is a deadly neurological complication of Plasmodium falciparum infection resulting in
high mortality or severe cognitive deficit. Drug resistance, low efficacy of new therapeutics, and unknown
mechanism of pathology and host immune interactions highlight the urgent need to develop solutions for this
tremendous global issue. Work from our lab and others have shown that leukocyte accumulation in the brain is
correlated with CM onset and severity, establishing a vital role of the immune system in pathology. The roles of
some immune cell subsets are well-established such as that of CD8 T cells which have been shown to mediate
blood-brain barrier disruption and vascular permeability in the late stages of infection. However, the role of the
antigen-presenting cell (APC) that initiates this CD8 T cell response remains elusive. Our lab will employ novel
cell-type specific deletion of the two MHC class I molecules found in C57BL/6 mice (H-2Kb and H-2Db) in order
identify this cell type. Mice deficient in either class I molecule on dendritic cells ((DC)s) are protected from
cerebral malaria. Therefore, in this proposal we plan to adoptively transfer in class I sufficient, pre-sorted DCs
of established subsets to identify the DC capable of initiating the CD8 T cell responses and blood-brain barrier
(BBB) disruption seen in CM. Identifying and characterizing this cell type will have broad implications in the
field ranging from fundamental insights into pathogenesis as well as improvement of vaccine strategies. After
addressing the initiating event we will characterize the pathologic outcome. CM is clinically characterized by
VEGF upregulation in the brain, and disruption of BBB tight junction proteins, vascular permeability, and
severe edema detectable by MRI. In our studies we employ small animal MRI and RNA in situ hybridization to
diagnose the presence of these biomarkers. We recently demonstrated that neurons are the cell type
responsible for VEGF transcriptional upregulation in the disease state. To address the role of VEGF in either
supporting or negating pathology we generated a new inducible mouse line capable of knocking out VEGF
specifically in neurons. After establishing infection we can induce knockout of neuronal-VEGF and assess
pathology. Elaborating upon the role of VEGF in CM will have therapeutic implications as well as provide
insight into methods of disease progression. Completion of these aims will allow us to address our central
hypothesis that a specific DC subset is required to elicit cytotoxic effector CD8 T cell-mediated BBB
permeability and neuronal VEGF upregulation; which reinforces pathology in ECM. These findings will prove
novel in any capacity and will contribute fundamental knowledge to several fields of study, provide mechanistic
insight into pathogenesis of malaria and determine potential targets of therapeutic intervention for the future.
项目总结/文摘:
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cori Elizabeth Fain其他文献
Cori Elizabeth Fain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 4.6万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 4.6万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 4.6万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 4.6万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 4.6万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 4.6万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 4.6万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 4.6万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 4.6万 - 项目类别: